The adequate assessment of prognosis is a crucial factor in the planning and therapy implementation of tumor patients. For this purpose, the TNM classification and the AJCC staging system are currently used in clinical routine. However, this is sometimes a complex and inaccurate procedure. For this reason, biomarkers are discussed in the literature in order to predict the clinical course of the patient more easily and accurate. In a pilot study, we could show that connexin 43 is an independent prognostic factor in oral squamous cell carcinoma (OSCC). In order to identify additional prognostic factors, we treated the human OSCC cell line UPCI-SCC-040 with TGFβ, to drive the cells into a more aggressive behaviour, and carried out a translatome analysis. We could identify new target genes of interest. Currently, we are validating the protein expression levels of those genes on a tissue microarray (TMA) from 60 OSCC patients. The aim of the project is to create a biomarker profile, which would be used in clinical routine for an improved prognosis prediction and thus a targeted therapy planning.
The presented project is being carried out in cooperation with the NGS Integrative Genomics (NIG) Core Unit of the Department of Human Genetics and the Institute of Pathology of the University Medical Center Göttingen.